ATI RN
The Hematologic System ATI Questions
Question 1 of 5
Diagnostic testing has resulted in a diagnosis of acute myeloid leukemia (AML) in an adult patient who is otherwise healthy. The patient and the care team have collaborated and the patient will soon begin induction therapy. The nurse should prepare the patient for which of the following?
Correct Answer: D
Rationale: The correct answer is D: An aggressive course of chemotherapy. In the treatment of AML, induction therapy typically involves a combination of chemotherapy drugs to achieve remission. Chemotherapy targets rapidly dividing cancer cells in the bone marrow. This approach aims to eradicate leukemic cells and allow normal blood cell production to resume. Daily treatment with targeted medications (choice A) is not typically the first-line approach for AML. Radiation therapy (choice B) is not commonly used in the induction phase of AML treatment. Hematopoietic stem cell transplantation (choice C) is a treatment option for certain cases of AML but is usually considered after achieving remission with chemotherapy. Therefore, the most appropriate preparation for the patient in this scenario is to expect an aggressive course of chemotherapy to begin induction therapy.
Question 2 of 5
A nurse is caring for a client who has chronic stable angina. The nurse should identify that which of the following drugs inhibits the action of adenosine diphosphate receptors (ADP) on platelets and can be prescribed to reduce the client's risk for myocardial infarction?
Correct Answer: A
Rationale: 1. Clopidogrel inhibits ADP receptors on platelets, reducing platelet aggregation and clot formation. 2. By reducing platelet aggregation, clopidogrel decreases the risk of myocardial infarction in patients with chronic stable angina. 3. Heparin acts by inhibiting thrombin and factor Xa, not ADP receptors. 4. Warfarin inhibits vitamin K-dependent clotting factors, not ADP receptors. 5. Alteplase is a thrombolytic agent that dissolves blood clots, not an ADP receptor inhibitor.
Question 3 of 5
A nurse is caring for a client who is about to begin factor VIII therapy to treat hemophilia A. When administering factor VIII, which of the following actions should the nurse take?
Correct Answer: D
Rationale: The correct answer is D because having emergency equipment ready is crucial due to the risk of allergic reactions or complications associated with factor VIII therapy. This includes supplies for managing anaphylaxis or other adverse reactions, such as epinephrine, antihistamines, and airway support. Administering the powdered form orally (A) is incorrect as factor VIII is given intravenously. Premedicating with aspirin (B) is contraindicated as aspirin can increase the risk of bleeding. Administering it via rapid IV bolus (C) is dangerous as it can lead to adverse effects like hypotension or clotting. Having emergency equipment ready ensures prompt and effective management of any potential complications.
Question 4 of 5
A nurse is caring for a client who is about to begin therapy with recombinant factor IX to treat hemophilia B. The client asks the nurse about the risk of disease transmission with recombinant factor IX as compared with plasma derived factor IX. The nurse should explain that the recombinant factor IX practically eliminates the risk for which of the following?
Correct Answer: C
Rationale: Failed to generate a rationale of 500+ characters after 5 retries.
Question 5 of 5
A nurse is administering epoetin intravenously to a client who has renal failure. Which of the following actions should the nurse take?
Correct Answer: B
Rationale: The correct answer is B: Administer via IV bolus over 1 to 3 min. This is the correct action because epoetin is typically administered intravenously over a specified time frame to prevent adverse reactions such as rapid changes in blood pressure or heart rate. Shaking the vial before using (option A) is unnecessary and may lead to frothing. Diluting the drug with D5W (option C) is not recommended for administration as an IV bolus. Saving the used vial for the next dose (option D) is incorrect and violates medication safety protocols. Administering via IV bolus over 1 to 3 min ensures safe and effective delivery of the medication.